<DOC>
	<DOCNO>NCT00863746</DOCNO>
	<brief_summary>The purpose study see sorafenib plus best supportive care ( i.e . addition non-cancer treatment patient would normally receive ) effective treatment lung cancer compare best supportive care alone . The safety tolerability two treatment group also compare . The goal study test ability sorafenib improve survival compare best supportive care alone .</brief_summary>
	<brief_title>A 3rd/4th Line Placebo-controlled Trial Sorafenib Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer ( NSCLC ) .</brief_title>
	<detailed_description>Acronyms use Adverse Events section : Disseminated intravascular coagulation ( DIC ) , International normalize ratio ( INR ) , Atrioventricular ( AV ) , Gastrointestinal ( GI ) , Not otherwise specify ( NOS ) , Common Terminology Criteria Adverse Events ( CTCAE ) , Absolute neutrophil count ( ANC ) , Central nervous system ( CNS ) , Acute respiratory distress syndrome ( ARDS ) , Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Ability understand willingness sign write Informed Consent Advanced relapse refractory predominantly non squamous NSCLC . The diagnosis must confirm cyto/ histologically Patients must measurable nonmeasurable disease At least two three prior standard treatment regimens NSCLC Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Male female subject &gt; /= 18 year age ( &gt; /=20 Japan ) time Informed Consent Life expectancy least 12 week Ability swallow oral medication Both men woman use adequate barrier birth control measure course trial 4 week completion trial Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior start study drug : Haemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; /= 100,000/Âµl Total bilirubin &lt; /=1.5 x upper limit normal Alanine aminotransferase ( ALT ) &lt; 2.5 x upper limit normal ( &lt; /= 5 x upper limit normal patient liver metastasis ) Aspartate aminotransferase ( AST ) &lt; 2.5 x upper limit normal ( &lt; /= 5 x upper limit normal patient liver metastasis ) Alkaline phosphatase &lt; 4 x upper limit normal ( &lt; /= 5 x upper limit normal patient liver metastasis ) Prothrombin Time ( PT ) International Normalized Ratio ( INR ) Partial Thromboplastin Time ( PTT ) &lt; 1.5 x upper limit normal Serum creatinine &lt; 1.5 x upper limit normal Calculated creatinine clearance &gt; /= 50 mL/min NSCLC patient predominantly squamous cell carcinoma histology Excluded medical condition : History cardiac disease : Congestive heart failure , Active coronary artery disease ( CAD ) , Cardiac arrhythmia ( &gt; Grade 2 NCICTCAE [ National Cancer InstituteCommon Terminology Criteria Adverse Events ] vers . 3.0 ) Uncontrolled hypertension despite two antihypertensive medication History Human immunodeficiency virus ( HIV ) infection chronic hepatitis B C History organ allograft Active clinically serious infection ( &gt; grade 2 NCICTCAE vers . 3.0 ) Patients seizure disorder require medication Patients evidence history bleed diathesis coagulopathy Patients undergoing renal dialysis Pulmonary hemorrhage/ bleed event &gt; /= CTCAE grade 2 within four week prior first dose study drug Any hemorrhage/ bleeding event &gt; /= CTCAE grade 3 within four week prior first dose study drug Thrombotic embolic venous arterial event cerebrovascular accident Pregnant breastfeeding woman . Any condition could affect absorption pharmacokinetics study drug Prior treatment Vascular Endothelial Growth Factor ( VEGF ) ( R ) inhibitor , include compound impact vascularity ( i.e . sunitinib , thalidomide , vandetanib , vascular disrupt agent [ VDA ] , VEGFtrap experimental agent class ) . Only bevacizumab ( Avastin ) permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Sorafenib</keyword>
</DOC>